- Home
- SOR vs ETON Comparison
SOR vs ETON Comparison
Compare SOR & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOR
- ETON
- Stock Information
- Founded
- SOR 1968
- ETON 2017
- Country
- SOR United States
- ETON United States
- Employees
- SOR N/A
- ETON N/A
- Industry
- SOR Investment Managers
- ETON Biotechnology: Pharmaceutical Preparations
- Sector
- SOR Finance
- ETON Health Care
- Exchange
- SOR Nasdaq
- ETON Nasdaq
- Market Cap
- SOR 361.3M
- ETON 329.8M
- IPO Year
- SOR N/A
- ETON 2018
- Fundamental
- Price
- SOR $42.35
- ETON $14.41
- Analyst Decision
- SOR
- ETON Strong Buy
- Analyst Count
- SOR 0
- ETON 3
- Target Price
- SOR N/A
- ETON $18.67
- AVG Volume (30 Days)
- SOR 16.2K
- ETON 243.0K
- Earning Date
- SOR 01-01-0001
- ETON 03-13-2025
- Dividend Yield
- SOR 7.24%
- ETON N/A
- EPS Growth
- SOR N/A
- ETON N/A
- EPS
- SOR 6.50
- ETON N/A
- Revenue
- SOR N/A
- ETON $34,677,000.00
- Revenue This Year
- SOR N/A
- ETON $22.25
- Revenue Next Year
- SOR N/A
- ETON $81.48
- P/E Ratio
- SOR $6.41
- ETON N/A
- Revenue Growth
- SOR N/A
- ETON 5.64
- 52 Week Low
- SOR $36.41
- ETON $3.03
- 52 Week High
- SOR $42.75
- ETON $15.00
- Technical
- Relative Strength Index (RSI)
- SOR 40.35
- ETON 62.22
- Support Level
- SOR $41.91
- ETON $13.09
- Resistance Level
- SOR $43.44
- ETON $14.35
- Average True Range (ATR)
- SOR 1.67
- ETON 1.13
- MACD
- SOR -0.11
- ETON 0.08
- Stochastic Oscillator
- SOR 27.40
- ETON 82.60
About SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.